Skip to main content
Assets
Pfizer logo
PFE.NYSE
Pfizer
Health Care · Pharmaceuticals

Global pharmaceutical company developing vaccines and medicines for oncology, inflammation, cardiovascular, and rare diseases including COVID-19 vaccine.

HQ: United StatesListed: United States

Historical AI Opinions

Audit every published iPulse AI forecast batch and immutable historical research document for Pfizer.

Historical AI Opinions

Pfizer Inc. (PFE.NYSE) AI OPINIONS & ADVISOR ANALYSIS

Read and compare the 8 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 19 March 2026Deep analysis 19 March 2026

PublisherRusslan Ramdowar
25 min readAudit All Past Forecasts
Warren Buffett AI advisor icon

Warren Buffett AI

Gemini 3 Pro
The Value Seeker FrameworkAI Researcher

Model rating

Strong Buy

5-Year Return Est.

+103.8%

Includes 4.35% annual net dividend contribution

1. Investment Thesis — Base Case

The base case envisions a methodical unlocking of as the market is forced to recognize Pfizer's stabilized owner economics. Over the next five years, the $5.7B cost realignment program protects while the $10B+ annual is directed heavily toward debt reduction. This discipline repairs the , paving the way for by 2027-2028. Simultaneously, the Seagen oncology assets will launch and scale, systematically replacing the revenue lost to the Eliquis and Ibrance patent cliffs. The net effect is a gradual from a distressed 8.5x P/E back to a historically normative 12x P/E.

  • Non-COVID operational revenue grows at a steady 6-8% CAGR, masking LOE drags.
  • The $5.7B cost reduction flows through to the bottom line, maintaining $2.80-$3.20 stability.
  • Debt paydown restores the , enabling share retirements that compound per-share value.
  • The Seagen ADC pipeline hits targeted milestones, confirming the M&A capital was not entirely squandered.
  • High pays owners handsomely to wait out the transition phase.

Historical prices and published forecast

Historical prices and published forecastObserved prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.18.0729.7541.4353.1164.79Mar 2021Sep 2023Mar 2026Sep 2028Mar 2031Forecast starts
  • Observed price
  • Published advisor forecast
Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.
View chart values
Historical prices and published forecast — published chart values
SeriesDateValue (USD)
Observed price2021-03-1835.9
Observed price2021-03-2836.3
Observed price2021-04-1337.1
Observed price2021-05-0540.0
Observed price2021-05-1539.9
Observed price2021-05-3139.0
Observed price2021-06-1140.3
Observed price2021-06-2739.1
Observed price2021-07-0839.6
Observed price2021-07-2441.6
Observed price2021-07-2942.8
Observed price2021-08-2049.0
Observed price2021-08-2548.0
Observed price2021-09-1544.5
Observed price2021-09-2144.0
Observed price2021-10-1241.9
Observed price2021-10-1742.4
Observed price2021-11-0849.5
Observed price2021-11-1350.5
Observed price2021-11-2953.6
Observed price2021-12-1053.4
Observed price2021-12-1560.9
Observed price2022-01-1155.8
Observed price2022-01-2252.7
Observed price2022-02-0153.9
Observed price2022-02-2347.9
Observed price2022-02-2847.8
Observed price2022-03-2153.8
Observed price2022-04-1253.0
Observed price2022-04-1750.7
Observed price2022-05-0348.6
Observed price2022-05-1450.9
Observed price2022-05-3053.6
Observed price2022-06-1051.1
Observed price2022-06-1548.6
Observed price2022-07-0652.0
Observed price2022-07-1252.5
Observed price2022-08-0249.7
Observed price2022-08-1349.8
Observed price2022-08-2946.0
Observed price2022-09-0946.8
Observed price2022-09-2544.5
Observed price2022-09-3044.4
Observed price2022-10-1142.1
Observed price2022-10-2746.4
Observed price2022-11-1748.4
Observed price2022-11-2248.8
Observed price2022-12-1451.7
Observed price2022-12-1951.5
Observed price2023-01-1047.8
Observed price2023-01-1545.9
Observed price2023-01-3143.7
Observed price2023-02-1143.3
Observed price2023-02-2740.8
Observed price2023-03-0939.5
Observed price2023-03-3140.7
Observed price2023-04-1041.6
Observed price2023-04-2638.7
Observed price2023-05-0239.0
Observed price2023-05-1836.6
Observed price2023-05-2938.2
Observed price2023-06-1440.0
Observed price2023-06-2437.7
Observed price2023-07-0535.7
Observed price2023-07-2137.0
Observed price2023-08-0135.3
Observed price2023-08-2236.8
Observed price2023-09-0734.3
Observed price2023-09-1234.1
Observed price2023-09-2833.2
Observed price2023-10-0933.2
Observed price2023-10-2530.3
Observed price2023-11-0530.7
Observed price2023-11-1629.5
Observed price2023-12-0228.9
Observed price2023-12-1226.7
Observed price2024-01-0329.7
Observed price2024-01-1928.3
Observed price2024-01-2427.8
Observed price2024-01-2927.2
Observed price2024-03-0126.8
Observed price2024-03-1228.0
Observed price2024-03-1827.7
Observed price2024-04-0826.4
Observed price2024-04-2425.7
Observed price2024-05-0528.0
Observed price2024-05-1028.2
Observed price2024-05-2628.8
Observed price2024-06-0628.8
Observed price2024-06-1627.5
Observed price2024-07-0828.0
Observed price2024-07-2430.0
Observed price2024-07-2931.3
Observed price2024-08-0928.6
Observed price2024-08-3028.5
Observed price2024-09-1529.5
Observed price2024-09-2129.4
Observed price2024-10-0128.7
Observed price2024-10-1729.2
Observed price2024-11-0826.7
Observed price2024-11-1326.1
Observed price2024-11-1825.1
Observed price2024-12-1525.7
Observed price2024-12-3126.6
Observed price2025-01-0626.8
Observed price2025-01-2226.1
Observed price2025-02-0126.3
Observed price2025-02-1225.6
Observed price2025-03-1126.4
Observed price2025-03-2125.9
Observed price2025-03-2725.1
Observed price2025-04-1222.0
Observed price2025-04-2824.0
Observed price2025-05-0922.3
Observed price2025-05-1923.0
Observed price2025-06-1024.3
Observed price2025-06-2024.1
Observed price2025-07-0625.6
Observed price2025-07-1225.4
Observed price2025-08-0223.7
Observed price2025-08-0724.4
Observed price2025-08-1825.3
Observed price2025-09-0824.9
Observed price2025-09-2524.0
Observed price2025-10-0526.4
Observed price2025-10-1624.5
Observed price2025-11-0624.5
Observed price2025-11-1225.9
Observed price2025-11-2825.2
Observed price2025-12-0825.9
Observed price2025-12-2424.9
Observed price2026-01-0425.3
Observed price2026-01-1525.6
Observed price2026-02-0527.0
Observed price2026-02-2727.6
Observed price2026-03-0426.7
Observed price2026-03-2527.0
Observed price2026-03-3127.9
Observed price2026-04-0527.8
Observed price2026-04-2626.8
Observed price2026-05-0226.4
Observed price2026-05-1825.7
Observed price2026-06-0826.1
Observed price2026-06-1925.3
Observed price2026-07-0523.8
Observed price2026-07-1625.1
Observed price2026-07-2624.7
Observed price2026-08-0626.4
Observed price2026-08-1726.9
Observed price2026-09-0229.0
Observed price2026-09-1427.7
Observed price2026-09-1627.5
Observed price2026-09-1827.7
Published advisor forecast2026-03-1827.3
Published advisor forecast2026-06-1827.9
Published advisor forecast2026-09-1828.7
Published advisor forecast2026-12-1829.9
Published advisor forecast2027-03-1829.6
Published advisor forecast2027-06-1830.7
Published advisor forecast2027-09-1831.7
Published advisor forecast2027-12-1833.2
Published advisor forecast2028-03-1832.6
Published advisor forecast2028-06-1834.5
Published advisor forecast2028-09-1835.9
Published advisor forecast2028-12-1837.3
Published advisor forecast2029-03-1838.1
Published advisor forecast2029-06-1839.2
Published advisor forecast2029-09-1838.1
Published advisor forecast2029-12-1839.6
Published advisor forecast2030-03-1840.8
Published advisor forecast2030-06-1842.4
Published advisor forecast2030-09-1843.2
Published advisor forecast2030-12-1844.1
Published advisor forecast2031-03-1845.0

2. Scenarios & Signals

Bull case

The bull case materializes if Pfizer's core turnaround is violently accelerated by clinical breakthroughs in its highly discounted obesity pipeline. If the ultra-long-acting assets demonstrate best-in-class efficacy, the market will instantly rerate the stock from a value-trap to a growth .

  • Phase 3 data forces a massive to 15x+ .
  • Seagen assets exceed the $10B 2030 target, proving management's genius.
  • Massive enables concurrent dividend hikes and aggressive .
  • The resulting cash geyser attracts momentum and growth capital, closing the instantly.

Bear case

The bear case unfolds if the proves weaker than modeled and R&D capital is permanently impaired. If Seagen assets fail in late-stage trials while Eliquis occurs faster than projected, will collapse.

  • Seagen pipeline attrition leads to massive and stagnant top-line growth.
  • IRA price negotiations compress legacy margins beyond the capacity of cost-cutting to offset.
  • Rising leverage forces a protective dividend cut, violating the core thesis for the income investor base.
  • The stock lingers as a perpetual , trading at 6-7x declining earnings.

Current crowd narrative

The prevailing consensus trade treats Pfizer as a terminal melting ice cube. The crowd is anchored entirely to the post-pandemic revenue collapse and the impending '' for Eliquis and Ibrance. Financial media fixates on the leveraged resulting from the $43B Seagen acquisition, concluding that management overpaid and trapped the company in a low-growth, high-debt paradigm. Consequently, the market ignores the durable non-COVID growth and prices the asset as if its future cash flows will steadily decay to zero.

Alpha-gap assessment

The lies in the arithmetic of owner's earnings and cash flow generation. The market fixates on top-line revenue stagnation caused by the (LOE) cliff, systematically ignoring that Pfizer is executing a $5.7B cost realignment and generating >$10B in annual . This cash covers the dividend while rapidly the . At 8.5x earnings, the market implies zero beyond 2030, entirely discounting the 60-program . The blind spot is treating a cyclical R&D transition as a permanent .

Convergence catalyst

Sustained sequential quarters of non-COVID operational revenue growth exceeding 6%, combined with management formally declaring the completion of the phase and the reinstatement of . This structural shift in will definitively signal that the LOE valley has been bridged.

Complete advisor preview locked

Unlock this report and every AI Advisor

Sign in to check your access, or upgrade to the Base plan to read this report and open every advisor.

Sign in to check accessView Base planReturn to latest AI Consensus